Compare Novavax Inc (NVAX) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs PAGSEG Inc — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while PAGSEG Inc trades at $11.16 (market cap $2.94B). The key difference: PAGSEG Inc is the larger of the two by market cap, and PAGSEG Inc pays a 10.49% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and PAGSEG Inc for 26 Days on average.
| NVAX | PAGS | |
|---|---|---|
Market Cap | $1.82B | $2.94B |
Volume | 6,198,505 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $12.56 | $12.00 |
52-Week Low | $6.22 | $8.44 |
Typical Hold Time | 59 Days | 26 Days |
Enterprise Value | $1.39B | $11.02B |
Dividend Yield | — | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
PAGS trades at $11.16, up 6.18% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 7.1 and net income margin of 10.45%. Recent Q2 2026 earnings beat expectations at $0.41 per share. The company maintains a dividend yield with a $0.28 payment scheduled for September 2026. Revenue growth remains stable at $20.6B for 2026 with improving profitability.
PAGS presents a compelling value opportunity with attractive valuation multiples and consistent earnings performance. Key risks include competitive pressures in digital banking and macroeconomic sensitivity in Brazil. Analyst consensus is strongly bullish with 15 buy ratings and a $10.70 price target, though the current price exceeds this target, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
